Overview

Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.

Phase:

Phase 4

Details

Lead Sponsor:

Alcon Research

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions
Travoprost